#### **BIOCRYST PHARMACEUTICALS INC**

Form 4 April 05, 2006

### FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to

Section 16. Form 4 or

Form 5 obligations

may continue. See Instruction STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

(Last)

1. Name and Address of Reporting Person \* BENNETT J CLAUDE

2190 PARKWAY LAKE DRIVE

2. Issuer Name and Ticker or Trading

Symbol

**BIOCRYST PHARMACEUTICALS INC [BCRX]** 

(First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)

(7:m)

04/03/2006

(Street) Filed(Month/Day/Year)

4. If Amendment, Date Original

**OMB** 

Number:

Expires:

response...

**OMB APPROVAL** 

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_X\_ Director 10% Owner Other (specify X\_ Officer (give title below) below)

President 6. Individual or Joint/Group Filing(Check

Applicable Line) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

BIRMINGHAM, AL 35244-

(Ctata)

(City)	(State)	(Zip) Tab	le I - Non-	Derivative	Secur	ities Acqui	red, Disposed of	, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit or Dispos (Instr. 3,	ed of (		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common	0.440.242.00.6	0.440.240.006	Code V	Amount	(D)	Price \$		_	
Stock	04/03/2006	04/03/2006	M	10,000	A	16.375	43,555	D	
Common Stock	04/03/2006	04/03/2006	M	684	A	\$ 16.375	44,239	D	
Common Stock	04/03/2006	04/03/2006	S	912 (1)	D	\$ 18	43,327	D	
Common Stock	04/03/2006	04/03/2006	S	3,240 (1)	D	\$ 18.01	40,087	D	
Common Stock	04/03/2006	04/03/2006	S	1,900 (1)	D	\$ 18.02	38,187	D	

#### Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Common Stock	04/03/2006	04/03/2006	S	1,912 (1)	D	\$ 18.04 36,275	D
Common Stock	04/03/2006	04/03/2006	S	2,036 (1)	D	\$ 18.05 34,239	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

I	. Title of Derivative Security Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	Secu Acqu or Di (D)	rities nired (A) isposed of r. 3, 4,	6. Date Exercise Expiration Date (Month/Day/Y	e	7. Title and L Underlying S (Instr. 3 and	Securities
					Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
(	Stock Option	\$ 16.375	04/03/2006	04/03/2006	M		684	12/31/1997	12/30/2006	Common Stock	684
(	Stock Option	\$ 16.375	04/03/2006	04/03/2006	M		10,000	12/31/1997	12/30/2006	Common Stock	10,000

# **Reporting Owners**

Reporting Owner Name / Address	Keiationsnips						
	Director	10% Owner	Officer	Other			
BENNETT J CLAUDE 2190 PARKWAY LAKE DRIVE BIRMINGHAM, AL 35244-	X		President				

# **Signatures**

Michael	
Richardson	04/05/2006
**Signature of Reporting Person	Date

2 Reporting Owners

#### Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (2) Options were exercised due to grants expiring by year end
- (3) Exercise pursuant to 10b5-1 rule of the Securities Exchange Act of 1934
- (1) Sale of stock is pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.